Voyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of ($0.46), $0.05 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $15.34 million versus the consensus estimate of $9.19 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.